Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Ligand Pharmaceuticals (LGNYZ) over the last 14 years, with Q3 2025 value amounting to $22.7 million.

  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability fell 5114.0% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year decrease of 5114.0%. This contributed to the annual value of $32.5 million for FY2024, which is 5801.73% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Non-Current Deferred Tax Liability stood at $22.7 million for Q3 2025, which was down 5114.0% from $32.2 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability's 5-year high stood at $77.5 million during Q4 2023, with a 5-year trough of $22.7 million in Q3 2025.
  • In the last 5 years, Ligand Pharmaceuticals' Non-Current Deferred Tax Liability had a median value of $39.5 million in 2022 and averaged $44.8 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Non-Current Deferred Tax Liability skyrocketed by 36658.28% in 2021, and later tumbled by 5801.73% in 2024.
  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability (Quarter) stood at $72.3 million in 2021, then rose by 4.53% to $75.6 million in 2022, then increased by 2.5% to $77.5 million in 2023, then plummeted by 58.02% to $32.5 million in 2024, then plummeted by 30.29% to $22.7 million in 2025.
  • Its Non-Current Deferred Tax Liability stands at $22.7 million for Q3 2025, versus $32.2 million for Q2 2025 and $29.4 million for Q1 2025.